Erbitux® 5mg
cetuximab
Terapeutic indications
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer:
- In combination with irinotecan-based chemotherapy,
- In 1st line in combination with FOLFOX,
- As a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:
- In combination with radiation therapy for locally advanced disease,
- In combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
Choose an indication
Select one of the indications below for more information about the safety and efficacy of Erbitux®